Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study

Table 3 Risks of severe (grade 3+) adverse events during first 6 months of RR TB treatment

Characteristic	Description	sHR^a	95 % CI
Age category	10–24 years	0.70	0.31–1.58
	25–39 years	Referent
	40–54 years	0.92	0.61–1.39
	55 years +	1.93	0.85–4.37
HIV and CD4 status	HIV negative	Referent
	HIV+, CD4 > 100 cells/mm³	1.81	0.84–3.89
	HIV+, CD4 ≤ 100 cells/mm3	2.76	1.30–5.84
HIV and ART status	HIV negative	Referent
	HIV+, initiated ART prior to RR TB	1.77	0.83–3.77
	HIV+, initiated ART with or after RR TB	3.07	1.46–6.46
	HIV+, not on ART	1.15	0.43–3.10
Weight (kg)	Weight >51 kg	Referent
Weight (kg)	Low weight (≤50 kg)	1.43	0.97–2.10
Prior TB treatment	No TB history reported	Referent
	History of first-line TB treatment	1.33	0.85–2.07
	History of streptomycin for TB treatment	3.49	1.52–8.02
Referring site	Outpatient facility	Referent
Referring site	Inpatient facility	1.11	0.74–1.70
Sex	Female	Referent
Sex	Male	0.83	0.57–1.22
Smear microscopy	Sputum smear negative or not reported	Referent
Smear microscopy	Sputum smear positive (scanty or higher)	1.00	0.69–1.47
Presenting symptom	No cough	Referent
Presenting symptom	Any cough	1.37	0.90–2.08
Co-morbidities^b	No reported pre-existing renal insufficiency, liver or psychiatric disorder	Referent
	Pre-existing renal, liver, or psychiatric condition	0.47	0.11–1.93

Bolded values are statistically significant at p-value < 0.05
ART antiretroviral therapy, RR TB rifampicin resistant tuberculosis, sHR subdistribution hazard ratio
^asHR crude analysis from competing risk regression accounting for death and loss from treatment
^bNo pregnant women had a documented severe AE prior to censoring

ISSN: 1471-2334